✦ LIBER ✦

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Scribed by Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; Peter C. Fong; Kristin Kowal; Candice McCoy; Herbert Wiesinger; Will Steward; Johann De Bono

Publisher: Springer
Year: 2009
Tongue: English
Weight: 253 KB
Volume: 64
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-0968-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation and pharmacoki

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

✍ E. Gabriela Chiorean; Srikar Malireddy; Anne E. Younger; David R. Jones; Mary-Ja 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

Phase I, dose escalation and pharmacokin

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

A phase I dose-escalation and pharmacoki

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer

✍ L. Q. M. Chow; N. Blais; D. J. Jonker; S. A. Laurie; S. G. Diab; C. Canil; M. Mc 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 312 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A two-part Phase II study of cediranib i

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

✍ Claire L. Mitchell; J. P. B. O’Connor; C. Roberts; Y. Watson; A. Jackson; S. Che 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 631 KB